RM Aris, DM Maia, IP Neuringer, K Gott, S Kiley, K Gertis and J Handy
Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill 27599-7524, USA.

Post-transplantation lymphoproliferative disorder (PTLD) is a widely recognized and often catastrophic complication of organ transplantation. The incidence of PTLD after lung transplantation ranges from 6.2 to 9.4% and is two-fold higher than that seen after organ transplantation of other organs. Primary Epstein-Barr virus (EBV) infection is a major risk factor for PTLD, but the incidence of PTLD in EBV seronegative (EBV-) patients seems to vary with type of organ transplant. The goal of this study was to quantify the risk of PLTD based on pre-lung transplantation EBV serostatus in lung transplant patients. Pre- and post-lung transplant serostatus was defined in 80 patients, and our six cases of PTLD occurred in this group. Six of 94 lung transplant patients (6.4%) who survived > 1 mo developed PTLD. All cases of PTLD involved thoracic structures at presentation and occurred in the first post-operative year. Patients who were EBV- before lung transplant were much more likely to develop PTLD than those who were seropositive (EBV+) (five of 15 [33%] versus one of 60 [< 2%], p < 0.001). Consistent with the prevailing adult (donor) EBV+ rate (85%), two of our EBV-patients remained EBV-after lung transplant. Therefore, the rate of PTLD was 42% in those with primary EBV infection. As compared with EBV-patients that remained tumor-free, those who developed PLTD had similar levels of immunosuppressants and doses of anti-viral therapy. We conclude that PLTD occurs predominantly in EBV- naive patients (risk approximately 1/3). EBV-patients should be monitored more closely after lung transplantation and, possibly, managed with lower immunosuppression. Our data also suggest that anti- viral therapy alone does not decrease the incidence of PTLD in high risk patients, PTLD can be successfully treated in most cases, and EBV- naive patients should not be excluded from lung transplant because their risk of death from PTLD is < 15%.

This article has been cited by other articles:

				W Chalermskulrat, N Sood, I P Neuringer, T M Hecker, L Chang, M P Rivera, L J Paradowski, and R M Aris Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation Thorax, June 1, 2006; 61(6): 507 - 513. [Abstract] [Full Text] [PDF]

				I. M. Ghobrial, T. M. Habermann, M. J. Maurer, S. M. Geyer, K. M. Ristow, T. S. Larson, R. C. Walker, S. M. Ansell, W. R. Macon, G. G. Gores, et al. Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients With Post-Transplantation Lymphoproliferative Disorders J. Clin. Oncol., October 20, 2005; 23(30): 7574 - 7582. [Abstract] [Full Text] [PDF]

				R. M. Kotloff, V. N. Ahya, and S. W. Crawford Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48. [Abstract] [Full Text] [PDF]

				J. E. Davis, M. A. Sherritt, M. Bharadwaj, L. E. Morrison, S. L. Elliott, L. M. Kear, J. Maddicks-Law, T. Kotsimbos, D. Gill, M. Malouf, et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD Int. Immunol., July 1, 2004; 16(7): 983 - 989. [Abstract] [Full Text] [PDF]

				R.M. Kotloff and V.N. Ahya Medical complications of lung transplantation Eur. Respir. J., February 1, 2004; 23(2): 334 - 342. [Abstract] [Full Text] [PDF]

				P. Lee, O. A. Minai, A. C. Mehta, M. M. DeCamp, and S. Murthy Pulmonary Nodules in Lung Transplant Recipients: Etiology and Outcome Chest, January 1, 2004; 125(1): 165 - 172. [Abstract] [Full Text] [PDF]

				B. D. Reams, H. P. McAdams, D. N. Howell, M. P. Steele, R. D. Davis, and S. M. Palmer Posttransplant Lymphoproliferative Disorder: Incidence, Presentation, and Response to Treatment in Lung Transplant Recipients Chest, October 1, 2003; 124(4): 1242 - 1249. [Abstract] [Full Text] [PDF]

				W. Chalermskulrat, I. P. Neuringer, J. L. Schmitz, D. J. Catellier, M. J. Gurka, S. H. Randell, and R. M. Aris Human Leukocyte Antigen Mismatches Predispose to the Severity of Bronchiolitis Obliterans Syndrome After Lung Transplantation Chest, June 1, 2003; 123(6): 1825 - 1831. [Abstract] [Full Text] [PDF]

				F. J. Jenkins, D. T. Rowe, and C. R. Rinaldo Jr. Herpesvirus Infections in Organ Transplant Recipients Clin. Vaccine Immunol., January 1, 2003; 10(1): 1 - 7. [Full Text] [PDF]

				J. Collins, E. A. Kazerooni, J. Lacomis, H. P. McAdams, A. N. Leung, M. Shiau, J. Semenkovich, and R. B. Love Bronchogenic Carcinoma after Lung Transplantation: Frequency, Clinical Characteristics, and Imaging Findings Radiology, July 1, 2002; 224(1): 131 - 138. [Abstract] [Full Text]

				T. G. Phan, B. P. O'Neill, and P. J. Kurtin Posttransplant primary CNS lymphoma Neuro-oncol, October 1, 2000; 2(4): 229 - 238. [Abstract] [PDF]

				L. G. Singer, J. Theodore, M. K. Gould, S. M. Levine, and L. Angel Analysis of Results in Posttransplant Lymphoproliferative Disorder Chest, October 1, 2000; 118(4): 1227 - 1228. [Full Text] [PDF]

				A. H. COHEN, S. C. SWEET, E. MENDELOFF, G. B. MALLORY Jr., C. B. HUDDLESTON, M. KRAUS, M. KELLY, R. HAYASHI, and M. R. DEBAUN High Incidence of Posttransplant Lymphoproliferative Disease in Pediatric Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1252 - 1255. [Abstract] [Full Text]

				S. M. Levine, L. Angel, A. Anzueto, I. Susanto, J. I. Peters, E. Y. Sako, and C. L. Bryan A Low Incidence of Posttransplant Lymphoproliferative Disorder in 109 Lung Transplant Recipients Chest, November 1, 1999; 116(5): 1273 - 1277. [Abstract] [Full Text] [PDF]

				T. M. Egan, F. C. Detterbeck, M. R. Mill, K. K. Gott, J. B. Rea, J. McSweeney, R. M. Aris, and L. J. Paradowski Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group Ann. Thorac. Surg., August 1, 1998; 66(2): 337 - 346. [Abstract] [Full Text] [PDF]